These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 6695906)

  • 21. Modification of photodynamic therapy-induced hypoxia by fluosol-DA (20%) and carbogen breathing in mice.
    Fingar VH; Mang TS; Henderson BW
    Cancer Res; 1988 Jun; 48(12):3350-4. PubMed ID: 3130983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in plasma enzyme concentrations in response to blood substitution with perfluorocarbon emulsion in the conscious rat.
    Lowe KC; McNaughton DC
    Experientia; 1986 Dec; 42(11-12):1228-31. PubMed ID: 3780945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of various oxygenation conditions and fluosol-DA on cytotoxicity and antitumor activity of bleomycin in mice.
    Teicher BA; Holden SA; Cathcart KN; Herman TS
    J Natl Cancer Inst; 1988 Jun; 80(8):599-603. PubMed ID: 2453675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of moderate fluosol-DA hemodilution on gender specific metabolism of antipyrine.
    Shrewsbury RP; White LG
    Res Commun Chem Pathol Pharmacol; 1989 Jun; 64(3):455-62. PubMed ID: 2781142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experimental studies on fluosol DA administration in acute pancreatitis.
    Ohyanagi H; Ohashi O; Nakayama S; Yamamoto M; Okumura S; Saitoh Y
    Biomater Artif Cells Artif Organs; 1988; 16(1-3):585-94. PubMed ID: 3179491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic effect of infused Fluosol-DA/carbogen with ephedrine, flunarizine, or nitroprusside.
    Teicher BA; Holden SA; Northey D; Dewhirst MW; Herman TS
    Int J Radiat Oncol Biol Phys; 1993 Apr; 26(1):103-9. PubMed ID: 8482616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of moderate haemodilution with fluosol-DA or normal saline on ampicillin kinetics in the rat.
    Shrewsbury RP
    J Pharm Pharmacol; 1986 Sep; 38(9):647-52. PubMed ID: 2877063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Addition of a hypoxic cell selective cytotoxic agent (mitomycin C or porfiromycin) to Fluosol-DA/carbogen/radiation.
    Holden SA; Herman TS; Teicher BA
    Radiother Oncol; 1990 May; 18(1):59-70. PubMed ID: 2113698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.
    Teicher BA; Bernal SD; Holden SA; Cathcart KN
    Cancer Chemother Pharmacol; 1988; 21(4):281-5. PubMed ID: 3131032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of moderate haemodilution with Fluosol-DA or normal saline on low-dose phenytoin and (+/-)-5-(4-hydroxyphenyl)-5-phenylhydantoin kinetics.
    Shrewsbury RP; Lewis LM; Oliver SR
    J Pharm Pharmacol; 1987 May; 39(5):349-56. PubMed ID: 2886583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of moderate haemodilution with Fluosol-DA or Hespan on the nonmicrosomal acetylation of sulphadimidine in the rat.
    Shrewsbury RP; Hong DD; White LG; Gordon TR
    J Pharm Pharmacol; 1992 Feb; 44(2):84-8. PubMed ID: 1378493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protective effect of Fluosol-DA in acute cerebral ischemia.
    Peerless SJ; Ishikawa R; Hunter IG; Peerless MJ
    Stroke; 1981; 12(5):558-63. PubMed ID: 6795765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biocompatibility studies with a novel perfluorochemical emulsion.
    Bollands AD; Lowe KC; Sharma SK; Davis SS
    Biomater Artif Cells Artif Organs; 1988; 16(1-3):451-3. PubMed ID: 3179482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surgical use of fluosol-DA in Jehovah's Witness patients.
    Ohyanagi H; Nakaya S; Okumura S; Saitoh Y
    Artif Organs; 1984 Feb; 8(1):10-8. PubMed ID: 6703920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential enhancement of melphalan cytotoxicity in tumor and normal tissue by Fluosol-DA and oxygen breathing.
    Teicher BA; Holden SA; Rose CM
    Int J Cancer; 1985 Nov; 36(5):585-9. PubMed ID: 3932225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of Fluosol-DA and Hespan haemodilution on S-warfarin elimination in the rat.
    Shrewsbury RP; Hong DD
    J Pharm Pharmacol; 1990 Sep; 42(9):665-6. PubMed ID: 1706766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Fluosol-DA on the response of intracranial 9L tumors to X rays and BCNU.
    Teicher BA; Herman TS; Rose CM
    Int J Radiat Oncol Biol Phys; 1988 Nov; 15(5):1187-92. PubMed ID: 3141321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extracorporeal circulation with perfluorochemicals (Fluosol-DA).
    Hoshino S; Iwaya F; Igari T; Kanno M; Honda K
    J Cardiovasc Surg (Torino); 1982; 23(6):463-9. PubMed ID: 7153234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perfluorocarbon emulsion prevents eicoasanoid release in skeletal muscle ischemia and reperfusion.
    Gennaro M; Mohan C; Ascer E
    Cardiovasc Surg; 1996 Jun; 4(3):399-404. PubMed ID: 8782946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Experimental studies on the effect of perfluorochemicals in tumor irradiation].
    Shinoda J; Iwai T; Hattori T; Kondo H; Sakai N; Yamada H
    Gan No Rinsho; 1984 Jan; 30(1):53-8. PubMed ID: 6700116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.